Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases

Fujimura, Taku; Maekawa, Takeo; Katô, Hiroshi; Ito, Takamichi; Matsushita, Satoru; Yoshino, Koji; Fujisawa, Yasuhiro; Ishizuki, Shoichiro; Segawa, Kojiro; Yamamoto, Jun; Hashimoto, Akira; Kambayashi, Yahiko; Asano, Yoshihide

doi:10.1111/1346-8138.16786

Cited by 5 publications

(12 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No increase of AEs was observed in the second taxane. In line with our findings, Fujimura et al 5 Both PTX and DTX attach to the same binding site in the tubulin, prohibiting microtubule formation during mitosis. 4 However, non-cross-resistance of PTX and DTX in ovarian and breast cancer cell lines has been demonstrated, which could explain the efficacy of the second taxane regimen in CAS.…”

Section: Discussionsupporting

confidence: 93%

“…No increase of AEs was observed in the second taxane. In line with our findings, Fujimura et al 5 reported the other taxane as second‐line chemotherapy is more suitable than eribulin methylate or pazopanib, based on the safety profiles.…”

Section: Discussionsupporting

confidence: 92%

“…However, chemoresistance to taxanes often occurs in CAS 3,4 . Moreover, no standard second‐line treatment for taxane‐resistant CAS has been established 1,5 . Switching from one taxane to the other (i.e., PTX to DTX, or vice versa) is an option for malignant cancers, such as ovarian or breast cancer, when the first taxane is no longer effective 6–8 .…”

Section: Introductionmentioning

confidence: 99%

“…Switching from one taxane to the other (i.e., PTX to DTX, or vice versa) is an option for malignant cancers, such as ovarian or breast cancer, when the first taxane is no longer effective 6–8 . In CAS, the second taxane, an eribulin methylate regimen, and pazopanib can be second‐line treatments in CAS resistant to the first taxane 5 . Herein, we report the clinical response of the second taxane‐based chemotherapy in CAS patients with resistance to the first taxane.…”

Section: Introductionmentioning

confidence: 99%

“…[6][7][8] In CAS, the second taxane, an eribulin methylate regimen, and pazopanib can be second-line treatments in CAS resistant to the first taxane. 5 Herein, we report the clinical response of the second taxane-based chemotherapy in CAS patients with resistance to the first taxane.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy

Yonekura

Endo

Fujii

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

Cutaneous angiosarcoma (CAS) is a rare soft‐tissue sarcoma of vascular endothelial origin. Paclitaxel (PTX) and docetaxel (DTX) are used as systemic chemotherapy; however, chemoresistance often occurs in CAS. Switching one taxane to the other (i.e., PTX to DTX, or vice versa) is an option when the first taxane is no longer effective in malignant cancers such as ovarian or breast cancer. However, the efficacy of the same strategy in CAS has not been reported. Herein, we report the clinical response of switching one taxane‐based chemotherapy to the other in CAS patients with resistance to the first taxane. Twelve CAS patients were included for analyses. In all patients, the median overall survival from the start of the first taxane treatment was 29.0 months (range, 6.47–58.5). During the first taxane, the median PFS for all patients was 5.96 months (1.81–47.1). Similarly, the median (range) PFS for all patients during the second taxane was 5.87 months (1.60–18.2). Furthermore, the median OS was 22.7 months (PTX to DTX) and 39.5 months (DTX to PTX) (p = 0.307). The median PFS during the first taxane was 5.14 (PTX to DTX) and 12.5 months (DTX to PTX), respectively (p = 0.380). The median PFS during the second taxane was 3.5 (PTX to DTX) and 7.1 months (DTX to PTX), respectively (p = 0.906). The objective response rate, defined as the sum of complete response (CR) and partial response (PR) rates, was 16.7%. The disease control rate, defined as the sum of CR, PR, and stable disease rates, was 50%. The frequency of adverse events during the second taxane was the same between the two groups (p > 0.999). Our report suggests that CAS patients could benefit from the second taxane treatment if the tumor is resistant to the first taxane.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 92%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy

Yonekura

Endo

Fujii

et al. 2023

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol

Fujimura,

Yoshino,

Nakamura

et al. 2023

Experimental Dermatology

Self Cite

View full text Add to dashboard Cite

Cutaneous angiosarcoma (CAS) is an endothelial cell‐derived, highly aggressive type of vascular tumour. Although chemoradiotherapy with paclitaxel (PTX) is recognized as a first‐line therapy for CAS, second‐line therapy for CAS remains controversial, and there is no standard therapy for taxane‐resistant CAS. Plasminogen activator inhibitor‐1 (PAI‐1) is associated with poor clinical outcomes, and elevated levels of PAI‐1 in both tissue and serum are correlated with poor response to therapy in various cancers, including skin cancers. Since PAI‐1 protects endothelial cells from Fas ligand‐mediated apoptosis, PAI‐1 inhibition might induce apoptosis of endothelial cell‐derived tumours such as CAS. This is a single‐arm, open‐label, multi‐institutional, Phase 2 clinical trial to assess the efficacy and safety of PTX in combination with TM5614 (PAI‐1 inhibitor) in patients with PTX‐resistant CAS. PTX will be administered for 28 weeks, with oral administration of TM5614. The primary endpoint of this study will be the overall response rate (ORR) at 28 weeks after starting treatment (central image evaluation). The secondary endpoint will include the ORR at 28 weeks after starting treatment (investigator evaluation), ORR at 8 weeks and 16 weeks after initiation of treatment (central and investigator evaluation), progression‐free survival, overall survival, disease control rate and safety profiles. Assuming the null hypothesis of a response rate of 13.6% and an alternative hypothesis of 45%, a minimum of 15 patients are required to achieve a two‐sided, Type I error of 5% and power of 70% based on the exact binomial distribution. Data quality control will be conducted by a combination of centralized (remote) and on‐site monitoring. This study will contribute to the development of novel combination therapy for PTX‐resistant CAS patients, which remains an unmet clinical need.

show abstract

Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab

Amagai,

Fujimura,

Kambayashi

et al. 2023

Case Rep Oncol

View full text Add to dashboard Cite

Introduction: Chemoradiotherapy with taxanes is well-recognized as a first-line therapy for cutaneous angiosarcoma (CAS), but second-line therapy for CAS is still controversial. Case Presentation: In this report, we described a 75-year-old Japanese case of recurrent, tumor mutation burden-high CAS on the scalp treated with pembrolizumab. Our present case survived for 1 year despite of taxane refractory CAS with mediastinal lymph node metastasis, though the administration of anti-PD-1 Abs alone could not fully suppress the tumor progression of CAS. Conclusion: Since various factors such as pro-angiogenic molecules are correlated with the tumor progression in CAS, the administration of anti-PD-1 Abs alone could not fully suppress the tumor progression of CAS. Further novel anticancer drugs are needed in the future for the treatment of CAS.

show abstract

Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases

Cited by 5 publications

References 19 publications

Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy

Clinical benefit of switching from paclitaxel to docetaxel or vice versa in cutaneous angiosarcoma patients resistant to first taxane chemotherapy

Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol

Recurrent, Tumor Mutation Burden-High, Cutaneous Angiosarcoma of the Scalp Treated with Pembrolizumab

Contact Info

Product

Resources

About